CAI earnings: real EPS beat/miss history, analyst consensus Buy, P/E -9.89. Updated 2026-07-23.
Caris Life Sciences (CAI) Research Hub
Caris Life Sciences (CAI) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 24.34 USD (+1.29%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -9.89, market cap 4.38B. This hub links to the full technical, earnings and options research available for CAI.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 24.34 USD (+1.29%) |
| 52-week range | 15.18 USD – 28.32 USD |
| Trend regime | Range |
| 14-day RSI | 55.9 (Bullish) |
| Trailing P/E | -9.89 |
| Market cap | 4.38B |
| Dividend yield | 0.00% |
Available research for CAI
Covered Call on CAI: how it works, illustrative setup around the real 24.34 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on CAI: how it works, illustrative setup around the real 24.34 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on CAI: how it works, illustrative setup around the real 24.34 USD price, max profit/loss, breakeven and when to use it. Educational.
CAI technical analysis: range, last 24.34 USD, RSI 55.9, 52w range 15.18 USD–28.32 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is CAI in?
Caris Life Sciences (CAI) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is CAI in an uptrend or downtrend?
As of 2026-09-11, CAI is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is CAI's trailing P/E ratio?
CAI's trailing P/E is -9.89, with a market cap of 4.38B. See the earnings research page for full valuation detail.